Biologics and diagnostic techniques.

Acacia subsidiary announces acquisition of 7 medtech patent portfolios Acacia Research Corporation announced today that a subsidiary has acquired 7 medtech patent portfolios made up of over 150 patents and pending applications relating to medical devices, biologics and diagnostic techniques. ‘Acacia continues to increase the number of patent portfolios we control in the medical life and technology sciences sector,’ states Paul Ryan, CEO and President . ‘We are rapidly expanding our existence as a leader in patent licensing in the medical device, diagnostics and life sciences sectors.’.

A recent recipient of the inaugural Breakthrough Prize in Lifestyle Sciences, his focus on colorectal cancers forms the building blocks for much of modern cancer analysis, with profound implications for diagnostic and therapeutic strategies later on. The celebratory night time also included remarks from Penn Medication leaders J. Larry Jameson, MD, PhD, executive vice president of the University of Pennsylvania for the Health System and Dean of the Perelman College of Medicine, and Ralph W. Muller, CEO of the University of Pennsylvania Wellness System, and Daniel J.